Solventum Completes Sale of its Purification & Filtration Business to Thermo Fisher Scientific Inc.

Rhea-AI Summary

Solventum (NYSE: SOLV) has completed the sale of its Purification & Filtration (P&F) business to Thermo Fisher Scientific (NYSE: TMO) for $4.0 billion in cash. The company will receive net proceeds of $3.4 billion, primarily allocated to debt reduction.

Following this strategic divestiture, Solventum has updated its FY2025 guidance, projecting organic sales growth of 2.0-3.0% and raising its adjusted EPS range to $5.88-$6.03. The company expects operating margins at the high end of 20-21% range and reduced net interest expense of $400 million, down from $450 million previously forecasted.

Positive

• None.

Negative

• Modest organic sales growth projection of only 2.0-3.0%
• SKU exit impact reducing growth by approximately 50 basis points
• Significant ongoing transitional services obligations to Thermo Fisher

Insights

Corporate Strategy & M&A Specialist

Solventum's $4B divestiture strengthens balance sheet, reduces debt, and improves 2025 EPS outlook despite losing P&F revenue stream.

Solventum's $4 billion sale of its Purification & Filtration business to Thermo Fisher represents a significant strategic repositioning that accelerates the company's transformation plan. The transaction provides $3.4 billion in net proceeds primarily earmarked for debt reduction, directly addressing the company's leverage concerns that have likely weighed on its valuation.

This divestiture appears strategically sound as it allows management to streamline operations and focus on core business segments. The updated guidance is particularly telling - despite selling off a revenue-generating division, Solventum is increasing its adjusted EPS guidance by $0.08 on both ends of the range (from $5.80-$5.95 to $5.88-$6.03). This suggests the P&F business was either less profitable than other segments or that the interest expense reduction ($50 million less than previously estimated) more than offsets the lost operating income.

The maintained organic sales growth projection of +2.0% to +3.0% despite divesting a business unit indicates confidence in the remaining portfolio's growth trajectory. Management's commentary about enhanced flexibility for both organic and inorganic growth opportunities signals that this transaction is just one component of a broader strategic evolution.

The guidance for operating margins toward the high end of the 20%-21% range further supports the notion that divesting P&F may actually improve Solventum's overall margin profile. With $450-$550 million in projected free cash flow for 2025 even after this divestiture, Solventum maintains significant financial flexibility for future strategic initiatives beyond debt reduction.

Financial Analyst

Solventum's $4B divestiture strengthens financial position by reducing $3.4B in debt while improving EPS guidance despite lost revenue.

The financial implications of this transaction are substantial and predominantly positive. Solventum's ability to command a $4 billion purchase price for its P&F business provides immediate balance sheet relief, with $3.4 billion in net proceeds going toward debt reduction. This represents a significant deleveraging event that addresses one of the company's key financial challenges following its separation from 3M.

The revised financial guidance reveals important underlying dynamics. Despite losing the revenue contribution from the P&F business, Solventum is raising its EPS guidance by $0.08 on both ends of the range. This counter-intuitive improvement is driven by an expected $50 million reduction in interest expense (from $450M to $400M), which will more than offset the lost operating income from the divested business.

The maintenance of the original +2.0% to +3.0% organic sales growth guidance suggests that either the P&F business was growing at a similar rate to the company average or that the remaining segments are expected to accelerate to compensate for the divestiture. The projected operating margin trending toward the high-end of the 20%-21% range indicates the P&F segment may have been margin-dilutive relative to Solventum's remaining portfolio.

The unchanged free cash flow projection of $450-$550 million despite the divestiture is particularly noteworthy, suggesting either strong cash conversion in the remaining businesses or that the P&F segment was not a significant cash generator relative to its revenue contribution. The debt reduction will significantly improve Solventum's financial flexibility, potentially leading to improved credit ratings and lower capital costs going forward.

• Accelerates Solventum's business transformation to deliver long-term shareholder value
• Net proceeds will be used primarily to pay down debt

ST. PAUL, Minn., Sept. 2, 2025 /PRNewswire/ -- Solventum (NYSE: SOLV) today announced it has completed the sale of its Purification & Filtration business ("P&F") to Thermo Fisher Scientific Inc. (NYSE: TMO) ("Thermo Fisher") for $4.0 billion in cash before customary adjustments. 

"Completing the transaction is an important milestone in Solventum's three-phased transformation plan and positions us well to advance our capital allocation strategy as we reduce leverage and strengthen our balance sheet with enhanced flexibility to invest in organic and inorganic growth opportunities," said Bryan Hanson, chief executive officer of Solventum. "Looking ahead, we remain focused on strategic execution, ensuring we deliver even greater value to our customers, team members and investors."

As previously announced, Solventum will use the net proceeds from the sale of $3.4 billion primarily to pay down outstanding debt.

Updated Full-Year 2025 Guidance
Solventum is updating its full year 2025 guidance to reflect the partial year accretion of the accelerated P&F divestiture.

• Organic sales growth in the range +2.0% to +3.0% (+2.5% to +3.5% excluding ~50 bps of SKU exit impact); no change
• Increased adjusted EPS range to $5.88 to $6.03 from prior range of $5.80 to $5.95
• Free cash flow in the range of $450 million to $550 million; no change

Updated additional financial considerations

• Expect net interest expense of $400 million, from prior estimate of $450 million
• Expect operating margin to be toward the high-end 20% to 21% range for full year 2025

Solventum's updated full year 2025 guidance reflects the expected reduction of net interest expense, which will more than offset the financial impact of the divestiture of the P&F business and is subject to the timely completion of the recently announced tender offers.

Following the transaction close, Solventum will provide transitional services and perform certain manufacturing and distribution activities on behalf of Thermo Fisher.

Supplemental non-GAAP financial information to aid investors in comparing historical to continuing operations can be found on the company's investor relations webpage at investors.solventum.com.

Morgan Stanley & Co. LLC, Perella Weinberg Partners and J.P. Morgan Securities LLC served as financial advisors to Solventum, and Cleary Gottlieb Steen & Hamilton served as legal advisor to Solventum.

Forward-Looking Statements
This news release contains forward-looking information about Solventum's financial results and estimates and business prospects that involve substantial risks and uncertainties. In particular, statements regarding the future performance of Solventum, including guidance for 2025, statements relating to the sale of the P&F business, the anticipated benefits of the transaction, the anticipated use of proceeds from the transaction, and the timing, terms and completion of the tender offers are forward-looking statements. You can identify these statements by the use of words such as "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "guidance," "intends," "may," "outlook," "plans," "projects," "seeks," "sees," "should," "targets," "will," "would," and other words and terms of similar meaning in connection with any discussion of future operating or financial performance or business plans or prospects. Among the factors that could cause actual results to differ materially are the following: (1) the effects of, and changes in, worldwide economic, political, regulatory, international, trade and geopolitical conditions, natural disasters, war, public health crises, and other events beyond Solventum's control; (2) operational execution risks; (3) damage to our reputation or our brands; (4) risks from acquisitions, strategic alliances, divestitures and other strategic events; (5) Solventum's business dealings involving third-party partners in various markets; (6) Solventum's ability to access the capital and credit markets and changes in Solventum's credit ratings; (7) exposure to interest rate and currency risks; (8) the highly competitive environment in which Solventum operates and consolidation in the healthcare industry; (9) reduction in customers' research budgets or government funding; (10) the timing and market acceptance of Solventum's new product and service offerings; (11) ongoing working relationships with certain key healthcare professionals; (12) changes in reimbursement practices of governments or private payers or other cost containment measures; (13) Solventum's ability to obtain components or raw materials supplied by third parties and other manufacturing and related supply chain difficulties, interruptions, and disruptive factors; (14) legal and regulatory proceedings and legal compliance risks (including third-party risks) with regards to antitrust, Foreign Corrupt Practices Act (FCPA) and other anti-bribery laws, environmental laws, anti-kickback and false claims laws, privacy laws, tax laws, and other laws and regulations in the United States and other countries in which Solventum operates; (15) potential liabilities related to a broad group of perfluoroalkyl and polyfluoroalkyl substances, collectively known as "PFAS"; (16) risks related to the highly regulated environment in which Solventum operates; (17) risks associated with product liability claims; (18) climate change and measures to address climate change; (19) security breaches and other disruptions to information technology infrastructure; (20) Solventum's failure to obtain, maintain, protect, or effectively enforce its intellectual property ("IP") rights; (21) pension and postretirement obligation liabilities; (22) any failure by the 3M Company ("3M") to perform any of its obligations under the various separation agreements in connection with the separation from 3M (the "Spin-Off"); (23) any failure to realize the expected benefits of the Spin-Off; (24) a determination by the IRS or other tax authorities that the distribution or certain related transactions should be treated as taxable transactions; (25) expected financing transactions undertaken in connection with the separation and risks associated with additional indebtedness; (26) the risk that incremental costs of operating on a standalone basis (including the loss of synergies), costs of restructuring transactions and other costs incurred in connection with the separation will exceed Solventum's estimates; and (27) the impact of the Spin-Off on its businesses and the risk that the Spin-Off may be more difficult, time-consuming or costly than expected, including the impact on its resources, systems, procedures and controls, diversion of management's attention and the impact on relationships with customers, suppliers, employees and other business counterparties.

Changes in such assumptions or factors could produce significantly different results. A further description of these factors is located under "Cautionary Note Regarding Forward-Looking Statements" and "Risk Factors" in Solventum's periodic reports on file with the U.S. Securities & Exchange Commission. Solventum assumes no obligation to update any forward-looking statements discussed herein as a result of new information or future events or developments.

About Solventum
At Solventum, we enable better, smarter, safer healthcare to improve lives. As a new company with a long legacy of creating breakthrough solutions for our customers' toughest challenges, we pioneer game-changing innovations at the intersection of health, materials and data science that change patients' lives for the better — while empowering healthcare professionals to perform at their best. See how at Solventum.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/solventum-completes-sale-of-its-purification--filtration-business-to-thermo-fisher-scientific-inc-302543458.html

SOURCE Solventum

FAQ

What is the value of Solventum's P&F business sale to Thermo Fisher Scientific?

Solventum (NYSE: SOLV) sold its Purification & Filtration business to Thermo Fisher Scientific for $4.0 billion in cash, with net proceeds of $3.4 billion.

How will Solventum use the proceeds from the P&F business sale?

Solventum will primarily use the $3.4 billion net proceeds to pay down outstanding debt, strengthening its balance sheet and providing flexibility for future growth opportunities.

What is Solventum's updated EPS guidance for 2025 after the P&F sale?

Solventum increased its adjusted EPS guidance range to $5.88-$6.03 from the previous range of $5.80-$5.95 for full-year 2025.

What is Solventum's projected organic sales growth for 2025?

Solventum projects organic sales growth of 2.0-3.0% for 2025 (2.5-3.5% excluding approximately 50 basis points of SKU exit impact).

How will the P&F business sale affect Solventum's interest expenses?

The company expects net interest expense to decrease to $400 million from the prior estimate of $450 million, more than offsetting the financial impact of the P&F business divestiture.